Published in Expert Rev Mol Med on May 13, 2011
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des (2011) 1.47
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos (2012) 1.19
Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain (2013) 1.12
Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep (2013) 1.09
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther (2012) 0.94
Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol (2015) 0.93
Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro. Oncol Lett (2013) 0.89
A complete compilation of matrix metalloproteinase expression in human malignant gliomas. World J Clin Oncol (2012) 0.89
Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos (2012) 0.89
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. J Pharmacol Exp Ther (2012) 0.89
Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain. J Pharmacol Exp Ther (2013) 0.88
Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol (2013) 0.88
Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model. J Pharmacol Exp Ther (2015) 0.87
Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Clin Pharmacol Ther (2014) 0.86
The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. J Cereb Blood Flow Metab (2014) 0.86
Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther (2013) 0.86
Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opin Drug Deliv (2013) 0.85
Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor. Biomaterials (2015) 0.84
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci (2013) 0.84
Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget (2015) 0.83
Absence of human cytomegalovirus infection in childhood brain tumors. Am J Cancer Res (2015) 0.83
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. Oncotarget (2015) 0.83
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst (2015) 0.83
Contemporary murine models in preclinical astrocytoma drug development. Neuro Oncol (2014) 0.81
Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. Neuro Oncol (2015) 0.81
An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. PLoS One (2015) 0.80
Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model. PLoS One (2016) 0.79
CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5. J Neuroimmunol (2012) 0.79
Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B (2016) 0.79
The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo. PLoS One (2014) 0.77
Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas. Genomics Proteomics Bioinformatics (2013) 0.77
Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. PLoS One (2015) 0.77
CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol (2015) 0.76
A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer. Oncotarget (2016) 0.76
Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep (2016) 0.75
Frizzled fissure to improve central nervous system drug delivery? J Cereb Blood Flow Metab (2014) 0.75
Advancing Cardiovascular, Neurovascular, and Renal Magnetic Resonance Imaging in Small Rodents Using Cryogenic Radiofrequency Coil Technology. Front Pharmacol (2015) 0.75
Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Invest New Drugs (2013) 0.75
Chlorotoxin-conjugated onconase as a potential anti-glioma drug. Oncol Lett (2014) 0.75
The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells. Oncotarget (2016) 0.75
Primary Role for Kinin B1 and B2 Receptors in Glioma Proliferation. Mol Neurobiol (2016) 0.75
Drug Delivery to Melanoma Brain Metastases: Can Current Challenges Lead to New Opportunities? Pharmacol Res (2017) 0.75
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res (2011) 2.06
Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther (2003) 1.93
Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev (2008) 1.65
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57
P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther (2009) 1.56
De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res (2009) 1.49
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des (2011) 1.47
Drug efflux transporters in the CNS. Adv Drug Deliv Rev (2003) 1.37
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.30
Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res (2010) 1.28
Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J Neurooncol (2006) 1.27
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther (2012) 1.26
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther (2012) 1.25
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos (2012) 1.19
In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother (2007) 1.18
Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res (2003) 1.17
GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res (2013) 1.16
Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos (2012) 1.13
Distribution kinetics of a micelle-forming block copolymer Pluronic P85. J Control Release (2004) 1.09
P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos (2007) 1.06
Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol (2013) 1.02
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos (2008) 1.00
Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res (2005) 0.99
Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol (2007) 0.99
Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clin Cancer Res (2010) 0.98
Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res (2008) 0.98
Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos (2007) 0.97
Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab (2006) 0.97
Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos (2008) 0.96
Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther (2005) 0.95
Efficacy of nonviral gene transfer in the canine brain. J Neurosurg (2007) 0.95
Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother (2013) 0.94
Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther (2004) 0.94
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther (2012) 0.94
Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Mol Ther (2013) 0.93
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol (2004) 0.92
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol (2010) 0.91
Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol Cancer Ther (2011) 0.91
Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.90
Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain. J Neurosurg (2011) 0.90
Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos (2012) 0.89
CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release (2013) 0.89
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. J Pharmacol Exp Ther (2012) 0.89
Identification of a novel monoclonal antibody recognizing CD133. J Immunol Methods (2010) 0.89
Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett (2012) 0.89
Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci (2006) 0.89
Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine (2010) 0.88
Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J Pharm Sci (2008) 0.88
Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain. J Pharmacol Exp Ther (2013) 0.88
Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance. Mol Pharm (2012) 0.88
pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos (2011) 0.87
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin Cancer Res (2012) 0.87
Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther (2013) 0.86
OCT2 and MATE1 provide bidirectional agmatine transport. Mol Pharm (2010) 0.85
Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol (2009) 0.85
CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma. J Immunol (2013) 0.85
Mitoxantrone permeability in MDCKII cells is influenced by active influx transport. Mol Pharm (2007) 0.85
Oxygen is a master regulator of the immunogenicity of primary human glioma cells. Cancer Res (2011) 0.85
Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer. PLoS One (2012) 0.84
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci (2013) 0.84
Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos (2013) 0.84
Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS One (2010) 0.84
Utilizing transmembrane convection to enhance solute sampling and delivery by microdialysis: theory and in vitro validation. J Memb Sci (2010) 0.84
Measurement of drug release from microcarriers by microdialysis. J Pharm Sci (2005) 0.84
Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. J Immunother (2011) 0.83
Adenoviral-mediated gene transfer into the canine brain in vivo. Neurosurgery (2007) 0.82
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer (2012) 0.81
Identification and characterization of a novel scFv recognizing human and mouse CD133. Drug Deliv Transl Res (2013) 0.81
Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells. Mol Pharm (2010) 0.79
Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci (2006) 0.79
Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Res (2013) 0.79
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction. ACS Med Chem Lett (2012) 0.79
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction. J Med Chem (2014) 0.78
Emerging concepts in glioma biology: implications for clinical protocols and rational treatment strategies. Neurosurg Focus (2005) 0.78
Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. J Pharm Sci (2009) 0.77
Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res (2015) 0.77
MMuFLR: missense mutation and frameshift location reporter. Bioinformatics (2013) 0.77
9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. Cancer Chemother Pharmacol (2012) 0.77
Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res Treat (2006) 0.77
Separation methods that are capable of revealing blood-brain barrier permeability. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.75
Cardiac responses to the intrapericardial delivery of metoprolol: targeted delivery compared to intravenous administration. J Cardiovasc Transl Res (2011) 0.75
Biphasic Dependence of Glioma Survival and Cell Migration on CD44 Expression Level. Cell Rep (2017) 0.75
Drug transport studies using quantitative microdialysis. Methods Mol Med (2003) 0.75